Myles Brown
Cancer genomics


My laboratory explores the factors underlying the hormone-dependence of breast and prostate cancers. I am recognized for three seminal discoveries, including the role of p160 co-activators in steroid receptor action, the dynamic nature of co-regulator function, and the predominance of steroid receptors as enhancer-rather than promoter-binding factors.

I am today director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. I earned my M.D. from Johns Hopkins, and trained in internal medicine at the Brigham and Women’s Hospital. Following a fellowship in medical oncology at Dana-Farber and postdoctoral research at MIT, I joined the staff of Dana-Farber and the faculty of Harvard Medical School.


Ludwig Center at Harvard
450 Brookline Avenue
Boston, Massachusetts, U.S. 02215

T 617 632 3985
F 617 632 3408


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?